EDIT vs NTLA
EDIT and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEditas Medicine, Inc. | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $272.18M | $1.58B |
| P/S | 6.7x | 23.3x |
| Revenue growth (YoY) | 25.4% | 16.9% |
| Earnings growth (YoY) | 32.5% | 20.5% |
| EBIT margin | -394.9% | -651.7% |
| ROE | -3631.1% | -66.5% |
| 1y total return | +9.0% | -6.8% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: EDIT frente a NTLA
| Métrica | EDIT | NTLA |
|---|---|---|
| Valor final | $919 | $5.1K |
| Retorno total | -90.8% | -48.8% |
| CAGR | -20.8% | -6.3% |
| Volatilidad | 83.5% | 78.4% |
| Sharpe | 0.07 | 0.26 |
| Sortino | 0.12 | 0.38 |
| Caída máxima | -98.9% | -96.5% |
Basado en 2575 días de negociación comunes, 2016-05-06 → 2026-08-04 · tasa libre de riesgo 3.89% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)